Aurora A Kinase Inhibitor LY3295668 Erbumine

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Trials	Jurisdictions	First approval	First trial
All cancers	Phase1	Phase 1	1	3	—	—	Jul 16, 2019
Malignant Breast Neoplasm	Phase1	Phase 1	0	1	—	—	Aug 2, 2019
Malignant Lung Neoplasm	Phase1	Phase 1	0	1	—	—	Jul 16, 2019

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
RB1 Mutation1
Aurora A Kinase Inhibitor LY3295668 Erbumine

Clinical trials

Trials with this intervention (3)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–3 of 3 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04106219	A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma	active not recruiting	Phase 1	71	Eli Lilly and CompanyINDUSTRY	9	Aug 21, 2026	clinicaltrials
NCT03898791	A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer	completed	Phase 1